Understanding Inhibitory Neurotransmission in Drug-Resistant Epilepsy
Official title: Functional Study of Inhibitory and Excitatory Neurotransmission in the Nervous Tissue Resected From Human Brain: Understanding New Molecular Mechanisms and Discovering New Therapeutic Targets to Cure Drug-resistant Epilepsy.
Run by Neuromed IRCCS · NCT05459090 · Data updated 2026-11-12
This study is testing how certain brain receptors work in people with drug-resistant epilepsy to see if new treatments can help manage their condition better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Neuromed IRCCS Academic / other |
| Locations | 1 site (Pozzilli, Isernia) |
| Status | Recruiting |
| Started | July 29, 2022 |
| Main results expected | February 28, 2025 |
| Study ends | July 31, 2027 |
| Registry record updated | August 2, 2022 |
| Trial ID | NCT05459090 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with drug-resistant temporal lobe epilepsy.
✕Probably not a fit
Patients whose temporal lobe epilepsy is caused by stroke, ischemia, cavernous angiomas, or meningiomas may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the functional alterations of GABA-A receptors in patients with drug-resistant temporal lobe epilepsy. The researchers will utilize patch-clamp recordings to characterize GABA-A mediated currents and identify the receptor subunit composition. Additionally, the study will explore the modulation of inhibitory neurotransmission through selective neuroactive molecules to enhance GABA release in the epileptic brain. The ultimate goal is to gain insights that could lead to new therapeutic strategies for managing epilepsy.
Why it matters
Potential benefit: If successful, this study could lead to the development of novel treatments for patients with drug-resistant epilepsy.
How similar studies have gone: While the approach of modulating GABA-A receptor function is established, the specific focus on drug-resistant epilepsy and the proposed methodologies may offer novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with drug-resistant temporal lobe epilepsy. Exclusion Criteria: * Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.
Where it's running
-
IRCCS INM Neuromed
Pozzilli, Isernia, Italy Recruiting
Study contacts
- Principal investigator: katiuscia Martinello, Biology — Neuromed IRCCS
- Study coordinator: katiuscia Martinello, Biology
- Email: katiuscia.martinello@neuromed.it
- Phone: 0865915218
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Modified ketogenic diet for adults with drug-resistant epilepsy
This study tests whether a modified ketogenic diet can help adults with drug-resistant epilepsy see fewer seizures and feel better overall.
-
Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
This study tests whether low intensity focused ultrasound can help reduce seizures in adults with drug‑resistant epilepsy.
-
iVEAcare Neuromodulation System for drug‑resistant epilepsy: a feasibility look
This study tests whether the iVEAcare neuromodulation system is safe and can help reduce seizures and improve quality of life in people with drug‑resistant epilepsy.
-
Real-world use of the OneRF Ablation System for epilepsy
This registry collects real-world outcomes and device performance from patients with drug-resistant epilepsy who are treated with SEEG-guided RF ablation using the OneRF system.
-
Overnight Temporal Interference Stimulation for Temporal Lobe Epilepsy
This study tests whether overnight, non-invasive temporal interference stimulation to the hippocampus can reduce seizure-related brain activity and improve sleep in adults with drug-resistant temporal lobe epilepsy.
-
Biomarkers of Response to SEEG Thermocoagulation
This study tests biomarkers to see if they predict how well SEEG-guided radiofrequency thermocoagulation helps people with drug-resistant focal epilepsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.